Answers are grounded in this paper and cite their sources.
This review evaluates the therapeutic potential of propolis in mitigating cardio-kidney-metabolic syndrome and periodontal diseases, suggesting clinical implications.
Cardio-kidney-metabolic (CKM) syndrome and periodontal diseases are bi-directionally linked pathologies driven by systemic inflammation, oxidative stress, and metabolic dysregulation. Identifying pleiotropic therapeutic agents targeting this axis is a major clinical priority. This review evaluates the bio-cellular role of propolis, a natural resinous hive product, in mitigating CKM syndrome and periodontal disease. Propolis exerts robust protective effects by modulating key intracellular signaling pathways. Specifically, it upregulates nuclear factor erythroid 2-related factor 2 (Nrf2)-dependent antioxidant defenses, which subsequently interferes with redox-sensitive inflammatory triggers. Concurrently, it antagonizes pro-inflammatory signaling, including nuclear factor-kappa B (NF-κB), mitogen-activated protein kinase (MAPK), and NOD-, LRR- and pyrin domain-containing protein 3 (NLRP3) inflammasome cascades. Furthermore, propolis prevents tissue fibrosis and cellular apoptosis by inhibiting transforming growth factor-beta (TGF-β)/suppressor of mothers against decapentaplegic (Smad) and c-Jun N-terminal kinase (JNK)/extracellular signal-regulated kinase (ERK) pathways. By disrupting this systemic inflammatory-metabolic loop and reducing local periodontal pathogen loads, propolis emerges as a promising adjunctive therapy. Propolis represents a promising candidate adjunctive therapy, although further well-designed and standardized clinical trials are required to validate its efficacy and translational potential.
No takes yet. Share an insight, caveat, or question.
Chang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: